Again, I’m posting this yt video not because I agree with the speaker, but as an example of the level of discourse we often encounter when discussing rapamycin in the longevity context. The speaker here is a fully accredited and credentialed professor doing active research. Somewhat discouraging insofar as level of analytical power this gentleman brings to the subject.
70: Rapamycin and Longevity: What the Research Really Says with Dr. Ben Bikman (via Ben Bikman)
1 Like
Dr. Benjamin Bikman—Professor of Cell Biology, Academic Qualifications & Training
-
B.S. in Exercise Science – Brigham Young University (2003)
-
M.S. in Exercise Physiology – Brigham Young University (2005)
-
Ph.D. in Bioenergetics – East Carolina University (2008)
-
Postdoctoral Fellowship in Cardiovascular and Metabolic Diseases – Duke-NUS Graduate Medical School, Singapore (2008–2011)
Current Teaching & Academic Affiliation
-
Brigham Young University (BYU) (Provo, Utah): Full Professor in the Department of Cell Biology and Physiology (formerly Physiology and Developmental Biology), where he has been on the faculty since 2011 (promoted to Full Professor in 2022). He teaches undergraduate and graduate courses in cell biology and physiology (e.g., CELL 305, CELL 365, CELL 565) and directs the Laboratory of Obesity and Metabolism / BYU Diabetes Research Lab.
I. Executive Summary
In this lecture from The Metabolic Classroom, Dr. Benjamin Bikman—Professor of Cell Biology and biomedical researcher—provides a skeptical, metabolically focused critique of rapamycin as a human longevity therapeutic. Bikman acknowledges the robust preclinical literature demonstrating that rapamycin-mediated inhibition of the mechanistic target of rapamycin (mTOR) induces autophagy and extends lifespan in model organisms (e.g., yeast, nematodes, flies, and rodents by up to 60%). However, he argues that the off-label translation of rapamycin to humans for healthy lifespan extension is fraught with unjustified clinical risk, highlighting that pharmacological mTOR inhibition directly compromises muscle protein synthesis, induces metabolic derangements, and ignores the primacy of hyperinsulinemia in driving pathological mTOR overactivation.
Bikman contends that the anti-aging community’s vilification of dietary protein is biologically flawed. While amino acids stimulate mTOR via nutrient-sensing pathways, Bikman asserts that insulin is a vastly more potent, chronic activator of mTOR in human physiology. Restricting dietary protein to blunt mTOR risks accelerating sarcopenia and frailty—two of the strongest clinical predictors of all-cause mortality in aging populations—especially given that epidemiological and clinical data associate higher protein intake (particularly animal protein) with reduced mortality and preserved functional independence in adults aged 65 and older.
Crucially, Bikman posits that individuals seeking the longevity benefits of mTOR downregulation do not require an immunosuppressive pharmacological agent. Instead, he advocates for dietary carbohydrate restriction and intermittent fasting to lower fasting insulin, thereby naturally cycling mTOR down and disinhibiting autophagy without pharmacological side effects (such as dyslipidemia, impaired glucose tolerance via mTORC2 disruption, or blunted muscle hypertrophy). While Bikman’s emphasis on avoiding sarcopenia and maintaining insulin sensitivity is strongly backed by human clinical data, his complete dismissal of low-dose intermittent rapamycin fails to acknowledge the distinct pharmacokinetics of pulsed vs. continuous dosing, and his assertion that protein has negligible effects on insulin oversimplifies postprandial endocrine dynamics.
II. Insight Bullets
- Dr. Benjamin Bikman examines rapamycin through a cell biology lens, arguing that its clinical risks in healthy humans outweigh the speculative longevity benefits.
- The mechanistic target of rapamycin (mTOR) is an evolutionary conserved intracellular serine/threonine protein kinase governing cell growth, anabolism, and protein synthesis.
- Preclinical rodent models consistently demonstrate that pharmacological mTOR inhibition via rapamycin extends median and maximal lifespan by up to 60%.
- mTOR inhibition directly disinhibits cellular autophagy, facilitating the catabolism and lysosomal recycling of damaged organelles and misfolded proteins.
- Bikman emphasizes that skeletal muscle mass and functional strength are primary physiological determinants of healthspan and survival in elderly cohorts.
- Dietary amino acids activate mTOR to drive muscle protein synthesis, making chronic mTOR inhibition counterproductive for sarcopenia prevention.
- The longevity hypothesis advocating dietary protein restriction to suppress mTOR risks inducing muscle wasting and frailty in older adults.
- In populations aged 65 and older, observational data link higher protein consumption—specifically animal protein—with reduced all-cause mortality.
- Bikman argues that systemic hyperinsulinemia, rather than physiological dietary protein consumption, is the dominant chronic driver of pathological mTOR overactivation.
- Consuming refined starches and simple sugars drives sustained insulin spikes, maintaining continuous mTOR activation while suppressing basal autophagy.
- Bikman asserts that taking rapamycin while maintaining a high-carbohydrate, hyperinsulinemic diet represents an illogical and counterproductive metabolic strategy.
- Intermittent fasting and dietary carbohydrate restriction naturally lower circulating basal insulin, allowing cyclic downregulation of mTOR and permissive autophagic flux.
- Centenarian cohorts and long-lived familial lines consistently demonstrate exceptional insulin sensitivity and low fasting insulin concentrations.
- Long-lived animal models, such as the naked mole-rat, exhibit high baseline insulin sensitivity and tightly regulated glycemic control.
- Bikman references pioneer gerontologist Cynthia Kenyon’s early lifespan work in Caenorhabditis elegans to highlight how nutrient limitation extends lifespan.
- Continuous high-dose rapamycin therapy, as utilized in solid-organ transplantation, is clinically linked to impaired wound healing, aphthous stomatitis, and dyslipidemia.
- Bikman highlights that pharmacological mTOR inhibition disrupts normal endocrine signaling and lipid handling in peripheral metabolic tissues.
- Muscle protein synthesis requires episodic peaks in mTOR activation, meaning continuous suppression impairs muscular adaptation to resistance training.
- Bikman concludes that lifestyle-mediated insulin suppression achieves the cellular benefits of mTOR modulation without pharmacological toxicity.
- The speaker cautions against adopting off-label pharmaceutical longevity interventions that lack validated, randomized, long-term human endpoint trials.
